Sungsoon Fang,Jae Myoung Suh,Elizabeth Yu,Olivia Osborn,Denise Lackey,Eiji Yoshihara,Alessia Perino,Sandra Jacinto,Yelizaveta Lukasheva,Annette R. Atkins,Bernd Schnabl,Ruth T. Yu,David A. Brenner,Sally Coulter,Christopher Liddle,Kristina Schoonjans,Jerrold M. Olefsky,Alan R. Saltiel,Michael Downes,Ronald M. Evans,Changtao Jiang,Cen Xie,Fei Li,Limin Zhang,Robert G. Nichols,Kristopher W. Krausz,Jingwei Cai,Yunpeng Qi,Zhong-Ze Fang,Shogo Takahashi,Dhimant Desai,Shantu G. Amin,Andrew D. Patterson,Frank J. Gonzalez

Abstract:1 Nat Med. 2015 Feb;21(2):159–165. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance Sungsoon Fang, Jae Myoung Suh, Shannon M. Reilly, Elizabeth Yu, Olivia Osborn, Denise Lackey, Eiji Yoshihara, Alessia Perino, Sandra Jacinto, Yelizaveta Lukasheva, Annette R. Atkins, Alexander Khvat, Bernd Schnabl, Ruth T. Yu, David A. Brenner, Sally Coulter, Christopher Liddle, Kristina Schoonjans, Jerrold M. Olefsky, Alan R. Saltiel, Michael Downes and Ronald M. Evans Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, California, USA. Life Sciences Institute, University of Michigan, Ann Arbor, Michigan, USA. Department of Medicine, University of California San Diego, San Diego, California, USA. Metabolic Signaling, Institute of Bioengineering, School of Life Sciences, Ecole Polytechnique Federale de Lausanne, Switzerland. ChemDiv, Inc., San Diego, California, USA. Storr Liver Unit, Westmead Millennium Institute, Sydney Medical School, University of Sydney, Australia. Howard Hughes Medical Institute, Salk Institute for Biological Studies, La Jolla, California, USA. The systemic expression of the bile acid (BA) sensor farnesoid X receptor (FXR) has led to promising new therapies targeting cholesterol metabolism, triglyceride production, hepatic steatosis and biliary cholestasis. In contrast to systemic therapy, bile acid release during a meal selectively activates intestinal FXR. By mimicking this tissue-selective effect, the gut-restricted FXR agonist fexaramine (Fex) robustly induces enteric fibroblast growth factor 15 (FGF15), leading to alterations in BA composition, but does so without activating FXR target genes in the liver. However, unlike systemic agonism, we find that Fex reduces diet-induced weight gain, body-wide inflammation, and hepatic glucose production, while enhancing thermogenesis and browning of white adipose tissue (WAT). These pronounced metabolic improvements

Improvement of NASH and liver fibrosis through modulation of the gut-liver axis by a novel intestinal FXR agonist

Glycine-β-muricholic acid antagonizes the intestinal farnesoid X receptor-ceramide axis and ameliorates NASH in mice

Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities

Discovery of HPG1860, a Structurally Novel Nonbile Acid FXR Agonist Currently in Clinical Development for the Treatment of Nonalcoholic Steatohepatitis

Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease

Natural Products in the Modulation of Farnesoid X Receptor Against Nonalcoholic Fatty Liver Disease

Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists

FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid

Structure Optimization of 12β-O-γ-Glutamyl Oleanolic Acid Derivatives Resulting in Potent FXR Antagonist/Modulator for NASH Therapy

FXR: structures, biology, and drug development for NASH and fibrosis diseases

Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis

Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis

The role of FXR and TGR5 in reversing and preventing progression of Western diet-induced hepatic steatosis, inflammation, and fibrosis in mice

Characterization of EDP-305, a Highly Potent and Selective Farnesoid X Receptor Agonist, for the Treatment of Non-alcoholic Steatohepatitis

Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis

Design, synthesis and structure-activity relationship studies of novel partial FXR agonists for the treatment of fatty liver

Rational design of FXR agonists: a computational approach for NASH therapy

Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis

Design, synthesis, and biological studies of novel sulfonamide derivatives as farnesoid X receptor agonists

Intestinal FXR: A New Therapeutic Target for Nonalcoholic Fatty Liver Disease

Discovery of LH10, a Novel Fexaramine-Based FXR Agonist for the Treatment of Liver Disease